A Pilot Study to Test the Feasibility and Immunologic Impact of Sipuleucel-T (Provenge) Administered With or Without Anti-PD-1 mAb (CT-011) and Low Dose Cyclophosphamide in Men With Advanced Castrate-Resistant Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Cyclophosphamide (Primary) ; Pidilizumab (Primary) ; Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 15 Sep 2017 Status changed from suspended to discontinued due to drug supply issue.
- 28 Jun 2016 Status changed from recruiting to suspended.
- 13 Mar 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.